Shukui Qin
Nanchang University(CN)Guangxi University(CN)China Pharmaceutical University(CN)Nanjing General Hospital of Nanjing Military Command(CN)Jinyintan Hospital(CN)Jiangxi Provincial Academy of Medical Sciences(CN)Beijing Academy of Artificial Intelligence(CN)Jiangsu Cancer Hospital(CN)China Academy of Information and Communications Technology(CN)Nanjing Jiangning Hospital(CN)PLA Army Engineering University(CN)First Affiliated Hospital of Nanchang University(CN)Jinling Institute of Technology(CN)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Cholangiocarcinoma and Gallbladder Cancer Studies, Lung Cancer Treatments and Mutations, Hepatocellular Carcinoma Treatment and Prognosis
Most-Cited Works
- → Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer(2022)1,014 cited
- → Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)(2020)818 cited
- → Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma(2021)772 cited
- → Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification(2011)674 cited
- → The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer(2021)662 cited
- → Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study(2014)